Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Incidence Trend and Management of Thyroid Cancer - What has Changed in the Last Years: Own Experience and Literature Review

Version 1 : Received: 19 September 2023 / Approved: 20 September 2023 / Online: 21 September 2023 (05:30:14 CEST)

A peer-reviewed article of this Preprint also exists.

Kaliszewski, K.; Diakowska, D.; Miciak, M.; Jurkiewicz, K.; Kisiel, M.; Makles, S.; Dziekiewicz, A.; Biernat, S.; Ludwig, M.; Ludwig, B.; Sutkowska-Stępień, K.; Sebastian, M.; Domosławski, P.; Sutkowski, K.; Wojtczak, B. The Incidence, Trend, and Management of Thyroid Cancer—What Has Changed in the Past Years: Own Experience and Literature Review. Cancers 2023, 15, 4941. Kaliszewski, K.; Diakowska, D.; Miciak, M.; Jurkiewicz, K.; Kisiel, M.; Makles, S.; Dziekiewicz, A.; Biernat, S.; Ludwig, M.; Ludwig, B.; Sutkowska-Stępień, K.; Sebastian, M.; Domosławski, P.; Sutkowski, K.; Wojtczak, B. The Incidence, Trend, and Management of Thyroid Cancer—What Has Changed in the Past Years: Own Experience and Literature Review. Cancers 2023, 15, 4941.

Abstract

Because of ambiguous and widely debated observations concerning incidence trend and management of TC, we performed this analysis. We drew attention to some events, such as “cancer screening activity,” introduction of noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP) to TC types, possibility of papillary thyroid microcarcinoma (PTMC) active surveillance (AS), occurrence of personalized medicine in TC management and finally COVID-19 pandemic time. Because of the opinion that all changes have been made mostly by PTC, we compared it to the rest of types of TC in terms of incidence, clinical and pathological characteristics and treatment. The prevalence of TC significantly increased from 5.15% in 2008 to 13.84% in 2015 and then significantly decreased to 1.33% in 2022 when the pandemic lasted (p<0.0001). A similar trend was observed for PTC, when the incidence significantly increased to 13.99% in 2015 and then decreased to 1.38% in 2022 (p<0.0001). At that time, the NIFTP category was introduced, and observation of PTMC began. The prevalence of FTC and MTC also increased until 2015 and then decreased. Significant differences in age, types of surgery, necessity of reoperation, pTNM, between PTCs and other types of TCs were observed. The average age was significantly lower in PTC patients than in patients with the remaining types of TC (p<0.0001). Four milestones, including NIFTP introduction, the possibility of PTMC AS, personalized cancer medicine and the COVID-19 pandemic, may have influenced the general statistics of TC.

Keywords

thyroid cancer management; incidence trends; NIFTP; PTC; personalized medicine; COVID-19; cancer screening activity

Subject

Public Health and Healthcare, Health Policy and Services

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.